Extravasation of polymeric nanomedicines across tumor vasculature

Advanced Drug Delivery Reviews

Volumn 63, Issue 8, 2011, Pages 623-639

  Danquah, Michael K ^a   Zhang, Xin A ^b   Mahato, Ram I ^a  

^a Department of Pharmaceutical Sciences ^*  (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Drug delivery; Extravasation; Nanomedicines; Tumor targeting; Tumor vasculature

Indexed keywords

ANTI-CANCER AGENTS; ANTICANCER DRUG; BLOOD SUPPLY; CANCER THERAPY; DRUG CARRIER; EXTRAVASATION; KEY FEATURE; MICRO-VASCULATURE; MICROVESSELS; MULTI-FUNCTIONAL; NANOMEDICINES; POLYMERIC CARRIERS; TUMOR MICROENVIRONMENT; TUMOR MICROVASCULATURE; TUMOR REGRESSION; TUMOR TARGETING; TUMOR VASCULATURE;

CHEMOTHERAPY; DRUG DELIVERY; FUNCTIONAL POLYMERS;

TUMORS;

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BEVACIZUMAB; BICALUTAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EMBELIN; EPIRUBICIN; EPOTHILONE B; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GLUTAMATE CYSTEINE LIGASE; IXABEPILONE; LCL 204; LIPOSOME; MACROGOL; MITOMYCIN C; N OLEOYLETHANOLAMINE; OBLIMERSEN; PACLITAXEL; POLOXAMER; POLYCAPROLACTONE; POLYCARBONATE; POLYHISTIDINE; POLYLACTIC ACID; POLYMER; TARIQUIDAR; UNCLASSIFIED DRUG; VALSPODAR;

BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CANCER STEM CELL; CAPILLARY; CELL INTERACTION; CELL PH; CELL PROLIFERATION; COLON CARCINOMA; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG POTENTIATION; DRUG RELEASE; DRUG STRUCTURE; DRUG TRANSPORT; ENDOTHELIUM CELL; EXTRAVASATION; HUMAN; HYDRAULIC CONDUCTIVITY; HYDROPHOBICITY; HYPERTENSION; HYPERTHERMIA; HYPOXIA; INTERSTITIAL FLUID; INTERSTITIUM; LYMPH VESSEL; LYMPHANGIOGENESIS; MICELLE; MICROVASCULARIZATION; MULTIDRUG RESISTANCE; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECTUM CARCINOMA; REVIEW; SOLID TUMOR; STROMA CELL; THYROID CARCINOMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERMEABILITY; POLYMERS;

EID: 79959963318     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2010.11.005     Document Type: Review

References (192)

1. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7:653-664.
2. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427:695.
3. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 2001, 46:149-168.
4. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
5. Liggins R.T., Burt H.M. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv. Drug Deliv. Rev. 2002, 54:191-202.
6. Du W., Hong L., Yao T., Yang X., He Q., Yang B., Hu Y. Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg. Med. Chem. 2007, 15:6323-6330.
7. Luke D.R., Kasiske B.L., Matzke G.R., Awni W.M., Keane W.F. Effects of cyclosporine on the isolated perfused rat kidney. Transplantation 1987, 43:795-799.
8. Onetto N., Canetta R., Winograd B., Catane R., Dougan M., Grechko J., Burroughs J., Rozencweig M. Overview of Taxol safety. J. Natl Cancer Inst. Monogr. 1993, 131-139.
9. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
10. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47:113-131.
11. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv. Drug Deliv. Rev. 2008, 60:899-914.
12. Danquah M., Li F., Duke C.B., Miller D.D., Mahato R.I. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm. Res. 2009, 26:2081-2092.
13. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 2009, 61:1203-1213.
14. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
15. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
16. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989, 6:193-210.
17. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 1992, 3:351-362.
18. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994, 54:3352-3356.
19. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
20. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 1996, 93:14765-14770.
21. Monsky W.L., Mouta Carreira C., Tsuzuki Y., Gohongi T., Fukumura D., Jain R.K. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin. Cancer Res. 2002, 8:1008-1013.
22. Jain R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 1998, 4:655-657.
23. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 1994, 271:58-65.
24. Jain R.K. 1995 Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors. Ann. Biomed. Eng. 1996, 24:457-473.
25. Reinhold H.S. Improved microcirculation in irradiated tumours. Eur. J. Cancer 1971, 7:273-280.
26. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987, 47:3039-3051.
27. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
28. Aukland K., Reed R.K. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol. Rev. 1993, 73:1-78.
29. Gutmann R., Leunig M., Feyh J., Goetz A.E., Messmer K., Kastenbauer E., Jain R.K. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 1992, 52:1993-1995.
30. Milosevic M., Fyles A., Hedley D., Pintilie M., Levin W., Manchul L., Hill R. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 2001, 61:6400-6405.
31. Less J.R., Posner M.C., Boucher Y., Borochovitz D., Wolmark N., Jain R.K. Interstitial hypertension in human breast and colorectal tumors. Cancer Res. 1992, 52:6371-6374.
32. Milosevic M., Fyles A., Hedley D., Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol. 2004, 14:249-258.
33. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
34. Gullino P.M., Grantham F.H., Smith S.H., Haggerty A.C. Modifications of the acid-base status of the internal milieu of tumors. J. Natl Cancer Inst. 1965, 34:857-869.
35. Thistlethwaite A.J., Leeper D.B., Moylan D.J., Nerlinger R.E. pH distribution in human tumors. Int. J. Radiat. Oncol. Biol. Phys. 1985, 11:1647-1652.
36. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49:6449-6465.
37. Helmlinger G., Yuan F., Dellian M., Jain R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3:177-182.
38. Vaupel P. Physiological properties of malignant tumours. NMR Biomed. 1992, 5:220-225.
39. Vaupel P., Schaefer C., Okunieff P. Intracellular acidosis in murine fibrosarcomas coincides with ATP depletion, hypoxia, and high levels of lactate and total Pi. NMR Biomed. 1994, 7:128-136.
40. Vaupel P., Kelleher D.K., Engel T. Stable bioenergetic status despite substantial changes in blood flow and tissue oxygenation in a rat tumour. Br. J. Cancer 1994, 69:46-49.
41. Izumi H., Torigoe T., Ishiguchi H., Uramoto H., Yoshida Y., Tanabe M., Ise T., Murakami T., Yoshida T., Nomoto M., Kohno K. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev. 2003, 29:541-549.
42. Vaupel P. Pathophysiology of Solid Tumors. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies 2009, 52-83. Springer, Berlin Heidelberg. M. Molls, P. Vaupel, C. Nieder, M.S. Anscher (Eds.).
43. Yamagata M., Hasuda K., Stamato T., Tannock I.F. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br. J. Cancer 1998, 77:1726-1731.
44. Helmlinger G., Sckell A., Dellian M., Forbes N.S., Jain R.K. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 2002, 8:1284-1291.
45. Stubbs M., McSheehy P.M., Griffiths J.R., Bashford C.L. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today 2000, 6:15-19.
46. Gerweck L.E. Tumor pH: implications for treatment and novel drug design. Semin. Radiat. Oncol. 1998, 8:176-182.
47. Bae Y., Jang W.D., Nishiyama N., Fukushima S., Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol. Biosyst. 2005, 1:242-250.
48. Bae Y., Nishiyama N., Fukushima S., Koyama H., Yasuhiro M., Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 2005, 16:122-130.
49. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 2005, 103:405-418.
50. Mohajer G., Lee E.S., Bae Y.H. Enhanced intercellular retention activity of novel pH-sensitive polymeric micelles in wild and multidrug resistant MCF-7 cells. Pharm. Res. 2007, 24:1618-1627.
51. Lee E.S., Kim D., Youn Y.S., Oh K.T., Bae Y.H. A virus-mimetic nanogel vehicle. Angew. Chem. Int. Ed Engl. 2008, 47:2418-2421.
52. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11:812-818.
53. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 2001, 93:266-276.
54. Cardenas-Navia L.I., Yu D., Braun R.D., Brizel D.M., Secomb T.W., Dewhirst M.W. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res. 2004, 64:6010-6017.
55. Kaneta T., Takai Y., Iwata R., Hakamatsuka T., Yasuda H., Nakayama K., Ishikawa Y., Watanuki S., Furumoto S., Funaki Y., Nakata E., Jingu K., Tsujitani M., Ito M., Fukuda H., Takahashi S., Yamada S. Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann. Nucl. Med. 2007, 21:101-107.
56. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62:3387-3394.
57. Comerford K.M., Cummins E.P., Taylor C.T. c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res. 2004, 64:9057-9061.
58. Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269:23757-23763.
59. Denny W.A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 2001, 36:577-595.
60. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
61. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006, 3:24-40.
62. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., Scheppke L., Stockmann C., Johnson R.S., Angle N., Cheresh D.A. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
63. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
64. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7:987-989.
65. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
66. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
67. Polyak K., Haviv I., Campbell I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25:30-38.
68. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
69. Micke P., Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45(Suppl 2):S163-S175.
70. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
71. Bellini A., Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 2007, 87:858-870.
72. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
73. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7:1028-1034.
74. Kim M., Turnquist H., Jackson J., Sgagias M., Yan Y., Gong M., Dean M., Sharp J.G., Cowan K. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin. Cancer Res. 2002, 8:22-28.
75. Scharenberg C.W., Harkey M.A., Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002, 99:507-512.
76. Hu L., McArthur C., Jaffe R.B. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br. J. Cancer 2010, 102:1276-1283.
77. Steinbach D., Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia 2007, 21:1172-1176.
78. Costello R.T., Mallet F., Gaugler B., Sainty D., Arnoulet C., Gastaut J.A., Olive D. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000, 60:4403-4411.
79. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., Munn L.L., Jain R.K. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
80. Leu A.J., Berk D.A., Lymboussaki A., Alitalo K., Jain R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000, 60:4324-4327.
81. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7:192-198.
82. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001, 7:186-191.
83. Fukumura D., Jain R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 2007, 101:937-949.
84. Isaka N., Padera T.P., Hagendoorn J., Fukumura D., Jain R.K. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 2004, 64:4400-4404.
85. Simionescu N. Cellular aspects of transcapillary exchange. Physiol. Rev. 1983, 63:1536-1579.
86. Renkin E.M. Cellular and intercellular transport pathways in exchange vessels. Am. Rev. Respir. Dis. 1992, 146:S28-S31.
87. Roberts W.G., Palade G.E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 1997, 57:765-772.
88. Neal C.R., Michel C.C. Transcellular gaps in microvascular walls of frog and rat when permeability is increased by perfusion with the ionophore A23187. J. Physiol. 1995, 488(Pt 2):427-437.
89. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363-1380.
90. Rubin P., Casarett G. Microcirculation of tumors. I. Anatomy, function, and necrosis. Clin. Radiol. 1966, 17:220-229.
91. Warren B.A. The vascular morphology of tumors. Tumor Blood Circulation 1979, 1-47. CRC Press, Boca Raton. H.I. Peterson (Ed.).
92. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6:559-593.
93. Takakura Y., Mahato R.I., Hashida M. Extravasation of macromolecules. Adv. Drug Deliv. Rev. 1998, 34:93-108.
94. Romero I.A., Radewicz K., Jubin E., Michel C.C., Greenwood J., Couraud P.O., Adamson P. Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci. Lett. 2003, 344:112-116.
95. Hasegawa H., Ushio Y., Hayakawa T., Yamada K., Mogami H. Changes of the blood-brain barrier in experimental metastatic brain tumors. J. Neurosurg. 1983, 59:304-310.
96. Groscurth P., Kistler G. Human renal cell carcinoma in the "nude" mouse: long-term observations (author's transl). Beitr. Pathol. 1977, 160:337-360.
97. Hirano A., Matsui T. Vascular structures in brain tumors. Hum. Pathol. 1975, 6:611-621.
98. Warren B.A. The ultrastructure of the microcirculation at the advancing edge of Walker 256 carcinoma. Microvasc. Res. 1970, 2:443-453.
99. Majno G., Shea S.M., Leventhal M. Endothelial contraction induced by histamine-type mediators: an electron microscopic study. J. Cell Biol. 1969, 42:647-672.
100. McDonald D.M., Thurston G., Baluk P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 1999, 6:7-22.
101. Roberts W.G., Palade G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 1995, 108(Pt 6):2369-2379.
102. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237:97-132.
103. Dvorak A.M., Kohn S., Morgan E.S., Fox P., Nagy J.A., Dvorak H.F. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J. Leukoc. Biol. 1996, 59:100-115.
104. Feng D., Nagy J.A., Hipp J., Dvorak H.F., Dvorak A.M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J. Exp. Med. 1996, 183:1981-1986.
105. Dvorak A.M., Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J. Histochem. Cytochem. 2001, 49:419-432.
106. Yuan F. Transvascular drug delivery in solid tumors. Semin. Radiat. Oncol. 1998, 8:164-175.
107. Rippe B., Haraldsson B. Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiol. Scand. 1987, 131:411-428.
108. Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990, 50:4478-4484.
109. Jain R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990, 9:253-266.
110. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2002, 160:985-1000.
111. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
112. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
113. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 1998, 95:4607-4612.
114. Provenzale J.M., Mukundan S., Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am. J. Roentgenol. 2005, 185:763-767.
115. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., Torchilin V.P., Munn L.L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002, 62:6831-6836.
116. Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., Hanahan D., McDonald D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 1998, 101:1401-1413.
117. Jain R.K., The Eugene M., Lecture Landis Award Delivery of molecular and cellular medicine to solid tumors. Microcirculation 1996, 4(1997):1-23.
118. Biedler J.L., Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 1970, 30:1174-1184.
119. Minko T. HPMA copolymers for modulating cellular signaling and overcoming multidrug resistance. Adv. Drug Deliv. Rev. 2010, 62:192-202.
120. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 2003, 3:1-19.
121. Doyle L.A., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22:7340-7358.
122. van Veen H.W., Konings W.N. The ABC family of multidrug transporters in microorganisms. Biochim. Biophys. Acta 1998, 1365:31-36.
123. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11:265-283.
124. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61:3458-3464.
125. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 1998, 95:15665-15670.
126. Minko T., Kopeckova P., Kopecek J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 1999, 16:986-996.
127. Hu Y.P., Jarillon S., Dubernet C., Couvreur P., Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother. Pharmacol. 1996, 37:556-560.
128. Doige C.A., Yu X., Sharom F.J. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim. Biophys. Acta 1993, 1146:65-72.
129. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 2002, 54:759-779.
130. Batrakova E.V., Li S., Alakhov V.Y., Elmquist W.F., Miller D.W., Kabanov A.V. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm. Res. 2003, 20:1581-1590.
131. Minko T., Batrakova E.V., Li S., Li Y., Pakunlu R.I., Alakhov V.Y., Kabanov A.V. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J. Control. Release 2005, 105:269-278.
132. Batrakova E.V., Li S., Brynskikh A.M., Sharma A.K., Li Y., Boska M., Gong N., Mosley R.L., Alakhov V.Y., Gendelman H.E., Kabanov A.V. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J. Control. Release 2010, 143:290-301.
133. Zhang Y., Tang L., Sun L., Bao J., Song C., Huang L., Liu K., Tian Y., Tian G., Li Z., Sun H., Mei L. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater. 2010, 6:2045-2052.
134. Li P.Y., Lai P.S., Hung W.C., Syu W.J. Poly(l-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules 2010, 11:2576-2582.
135. Li F., Lu Y., Li W., Miller D.D., Mahato R.I. Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. J. Control. Release 2010, 143:151-158.
136. Lu Y., Li C.M., Wang Z., Ross C.R., Chen J., Dalton J.T., Li W., Miller D.D. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J. Med. Chem. 2009, 52:1701-1711.
137. Shuhendler A.J., O'Brien P., Rauth A.M., Wu X.Y. On the synergistic effects of of doxorubicin and mitomycin C against breast cancer cells. Drug Metab. Drug Int. 2008, 22:201-233.
138. Potchen E.J., Kinzie J., Curtis C., Siegel B.A., Studer R.K. Effect of irradiation on tumor microvascular permeability to macromolecules. Cancer 1972, 30:639-643.
139. Gaber M.H., Wu N.Z., Hong K., Huang S.K., Dewhirst M.W., Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36:1177-1187.
140. Hauck M.L., Dewhirst M.W., Bigner D.D., Zalutsky M.R. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin. Cancer Res. 1997, 3:63-70.
141. Engin K. Biological rationale for hyperthermia in cancer treatment (II). Neoplasma 1994, 41:277-283.
142. Dewhirst M.W. Future directions in hyperthermia biology. Int. J. Hyperthermia 1994, 10:339-345.
143. Fujiwara K., Watanabe T. Effects of hyperthermia, radiotherapy and thermoradiotherapy on tumor microvascular permeability. Acta Pathol. Jpn 1990, 40:79-84.
144. Lefor A.T., Makohon S., Ackerman N.B. The effects of hyperthermia on vascular permeability in experimental liver metastasis. J. Surg. Oncol. 1985, 28:297-300.
145. Hosono M.N., Hosono M., Endo K., Ueda R., Onoyama Y. Effect of hyperthermia on tumor uptake of radiolabeled anti-neural cell adhesion molecule antibody in small-cell lung cancer xenografts. J. Nucl. Med. 1994, 35:504-509.
146. Schuster J.M., Zalutsky M.R., Noska M.A., Dodge R., Friedman H.S., Bigner D.D., Dewhirst M.W. Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues. Int. J. Hyperthermia 1995, 11:59-72.
147. Hauck M.L., Coffin D.O., Dodge R.K., Dewhirst M.W., Mitchell J.B., Zalutsky M.R. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int. J. Hyperthermia 1997, 13:307-316.
148. Kong G., Braun R.D., Dewhirst M.W. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001, 61:3027-3032.
149. Wilhelm D.L., Mason B. Vascular permeability changes in inflammation: the role of endogenous permeability factors in mild thermal injury. Br. J. Exp. Pathol. 1960, 41:487-506.
150. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., Bredesen D.E., Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 1999, 5:1032-1038.
151. Chen Y., Xu X., Hong S., Chen J., Liu N., Underhill C.B., Creswell K., Zhang L. RGD-Tachyplesin inhibits tumor growth. Cancer Res. 2001, 61:2434-2438.
152. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 2000, 18:1185-1190.
153. Netti P.A., Hamberg L.M., Babich J.W., Kierstead D., Graham W., Hunter G.J., Wolf G.L., Fischman A., Boucher Y., Jain R.K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl Acad. Sci. USA 1999, 96:3137-3142.
154. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57:4593-4599.
155. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
156. Lee C.G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., Park K.R., Ferrara N., Jain R.K., Suit H.D., Boucher Y. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000, 60:5565-5570.
157. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., Mino M., Cohen K.S., Scadden D.T., Hartford A.C., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Chen H.X., Shellito P.C., Lauwers G.Y., Jain R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10:145-147.
158. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., Heim W., Berlin J., Holmgren E., Hambleton J., Novotny W.F., Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 2005, 23:3502-3508.
159. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin. Oncol. 2004, 31:18-23.
160. Pietras K., Ostman A., Sjoquist M., Buchdunger E., Reed R.K., Heldin C.H., Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001, 61:2929-2934.
161. Pietras K., Stumm M., Hubert M., Buchdunger E., Rubin K., Heldin C.H., McSheehy P., Wartmann M., Ostman A. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 2003, 9:3779-3787.
162. Lammerts E., Roswall P., Sundberg C., Gotwals P.J., Koteliansky V.E., Reed R.K., Heldin N.E., Rubin K. Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int. J. Cancer 2002, 102:453-462.
163. Salnikov A.V., Roswall P., Sundberg C., Gardner H., Heldin N.E., Rubin K. Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab. Invest. 2005, 85:512-521.
164. Salnikov A.V., Iversen V.V., Koisti M., Sundberg C., Johansson L., Stuhr L.B., Sjoquist M., Ahlstrom H., Reed R.K., Rubin K. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 2003, 17:1756-1758.
165. Griffon-Etienne G., Boucher Y., Brekken C., Suit H.D., Jain R.K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 1999, 59:3776-3782.
166. Taghian A.G., Abi-Raad R., Assaad S.I., Casty A., Ancukiewicz M., Yeh E., Molokhia P., Attia K., Sullivan T., Kuter I., Boucher Y., Powell S.N. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 2005, 23:1951-1961.
167. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 2001, 74:47-61.
168. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 1999, 5:83-94.
169. Minko T., Kopeckova P., Pozharov V., Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 1998, 54:223-233.
170. Kopecek J., Kopeckova P., Minko T., Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 2000, 50:61-81.
171. Chipman S.D., Oldham F.B., Pezzoni G., Singer J.W. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int. J. Nanomedicine 2006, 1:375-383.
172. Singer J.W. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J. Control. Release 2005, 109:120-126.
173. Lavasanifar A., Samuel J., Kwon G.S. Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 2002, 54:169-190.
174. Yamamoto Y., Nagasaki Y., Kato Y., Sugiyama Y., Kataoka K. Long-circulating poly(ethylene glycol)-poly(D, L-lactide) block copolymer micelles with modulated surface charge. J. Control. Release 2001, 77:27-38.
175. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vasculature permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
176. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 2001, 74:47-61.
177. Harrington K.J., Mohammadtaghi S., Uster P.S., Glass D., Peters A.M., Vile R.G., Stewart J.S. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 2001, 7:243-254.
178. Gadelle F., Koros W., Schechter R. Solubilization of aromatic solutes in block copolymers. Macromolecules 1995, 28:4883-4892.
179. Nagarajan R., Barry M., Ruckenstein E. Unusual selectivity in solubilization by block copolymer micelles. Langmuir 1986, 2:210-215.
180. Xing L., Mattice W. Strong solubilization of small molecules by triblock-copolymer micelles in selective solvents. Macromolecules 1997, 30:1711-1717.
181. Tian M., Arca E., Tuzar Z., Webber S., Munk P. Light scattering study of solubilization of organic molecules by block copolymer micelles in aqueous media. J. Polym. Sci. B Pol. Phys. 1995, 33:1713-1722.
182. Zhang Y., Taiming L., Liu J. Low temperature and glucose enhanced T7 RNA polymerase-based plasmid stability for increasing expression of glucagon-like peptide-2 in Escherichia coli. Protein Expr. Purif. 2003, 29:132-139.
183. Latere Dwan'Isa J.P., Rouxhet L., Preat V., Brewster M.E., Arien A. Prediction of drug solubility in amphiphilic di-block copolymer micelles: the role of polymer-drug compatibility. Pharmazie 2007, 62:499-504.
184. Huynh L., Grant J., Leroux J.C., Delmas P., Allen C. Predicting the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods. Pharm. Res. 2008, 25:147-157.
185. Mahmud A., Patel S., Molavi O., Choi P., Samuel J., Lavasanifar A. Self-associating poly(ethylene oxide)-b-poly(alpha-cholesteryl carboxylate-epsilon-caprolactone) block copolymer for the solubilization of STAT-3 inhibitor cucurbitacin I. Biomacromolecules 2009, 10:417-478.
186. Forster A., Hempenstall J., Tucker I., Rades T. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int. J. Pharm. 2001, 226:147-161.
187. Marsac P.J., Shamblin S.L., Taylor L.S. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res. 2006, 23:2417-2426.
188. Liu J., Xiao Y., Allen C. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. Eur. J. Pharm. Sci. 2003, 93:132-143.
189. Danquah M., Fujiwara T., Mahato R.I. Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery. Biomaterials 2010, 31:2358-2370.
190. Li F., Danquah M., Mahato R.I. Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. Biomacromolecules 2010, 11:2610-2620.
191. Shuai X., Ai H., Nasongkla N., Kim S., Gao J. Micellar carriers based on block copolymers of poly(-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J. Control. Release 2004, 98:415-426.
192. Shuai X., Merdan T., Schaper A., Xi F., Kissel T. Core-cross-linked polymeric micelles as paclitaxel carriers. Bioconjug. Chem. 2004, 15:441-448.